Epoch Investment Partners Inc. Sells 1,102,139 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Epoch Investment Partners Inc. lessened its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 79.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 279,432 shares of the company’s stock after selling 1,102,139 shares during the quarter. Epoch Investment Partners Inc. owned about 0.11% of Maravai LifeSciences worth $2,423,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Jump Financial LLC purchased a new stake in shares of Maravai LifeSciences during the 4th quarter valued at $225,000. Principal Financial Group Inc. raised its stake in Maravai LifeSciences by 3,349.6% in the first quarter. Principal Financial Group Inc. now owns 410,197 shares of the company’s stock valued at $3,556,000 after buying an additional 398,306 shares during the last quarter. Performa Ltd US LLC boosted its holdings in Maravai LifeSciences by 112.4% in the fourth quarter. Performa Ltd US LLC now owns 6,000 shares of the company’s stock worth $39,000 after acquiring an additional 3,175 shares in the last quarter. Sivik Global Healthcare LLC purchased a new stake in shares of Maravai LifeSciences during the fourth quarter worth about $1,344,000. Finally, Jennison Associates LLC acquired a new position in shares of Maravai LifeSciences during the first quarter valued at about $3,415,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Wall Street Analysts Forecast Growth

MRVI has been the topic of several research analyst reports. The Goldman Sachs Group dropped their target price on shares of Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th. Craig Hallum began coverage on Maravai LifeSciences in a research report on Wednesday, April 10th. They issued a “buy” rating and a $15.00 target price on the stock. Finally, Robert W. Baird lifted their price target on Maravai LifeSciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, May 9th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $11.44.

Maravai LifeSciences Trading Up 2.0 %

Shares of MRVI opened at $9.34 on Monday. Maravai LifeSciences Holdings, Inc. has a 52 week low of $4.52 and a 52 week high of $12.10. The stock’s 50-day moving average price is $8.38 and its 200-day moving average price is $7.82. The company has a debt-to-equity ratio of 0.71, a quick ratio of 10.47 and a current ratio of 11.32.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). The company had revenue of $64.18 million during the quarter, compared to analyst estimates of $60.84 million. Maravai LifeSciences had a negative net margin of 47.81% and a negative return on equity of 4.28%. As a group, equities analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.15 EPS for the current year.

Insider Activity

In related news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $9.81, for a total value of $97,520,954.94. Following the completion of the transaction, the director now owns 20,150,005 shares of the company’s stock, valued at approximately $197,671,549.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.63% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.